Goldman Sachs
PLX icon

Goldman Sachs’s Protalix BioTherapeutics PLX Stock Holding History

Goldman Sachs’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,250
Closed -$82K – 7227
2014
Q2 		$82K Buy
+2,250
New +$90.8K ﹤0.01% 6634

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Goldman Sachs's PLX Position: Q1 2026 in Review

Goldman Sachs reduced its Protalix BioTherapeutics (PLX) stake by 4.4% in Q1 2026, selling an estimated $28.4K and leaving 251,345 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #5549.

Goldman Sachs first reported a position in PLX in Q2 2013 and has held it in 28 quarters since. The position peaked at $741K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Goldman Sachs held 251,345 shares of Protalix BioTherapeutics worth $545K as of Q1 2026.
  • Goldman Sachs sold 11,464 Protalix BioTherapeutics shares in Q1 2026, an estimated $28.4K.
  • Protalix BioTherapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5549 holding.
  • Goldman Sachs first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 28 quarters since.
  • Goldman Sachs's Protalix BioTherapeutics position peaked at $741K in Q1 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.